Helped patients live
longer
compared to another immunotherapy*

A clinical trial compared patients with advanced melanoma who received 10 mg/kg of KEYTRUDA every 2 weeks (279 patients) or 3 weeks (277 patients) with those who received ipilimumab (278 patients).

*KEYTRUDA was compared to ipilimumab.

  • Results From a Clinical Trial Comparing KEYTRUDA to Another Immunotherapy

    KEYTRUDA helped some patients live longer

    At the time of patient follow-up, 67% (185 of 277 patients) treated with KEYTRUDA every 3 weeks were alive, compared to 60% (166 of 278 patients) treated with ipilimumab; 33% (92 of 277 patients) treated with KEYTRUDA every 3 weeks were not alive at follow-up, compared to 40% (112 of 278 patients) treated with ipilimumab. KEYTRUDA given every 3 weeks was shown to reduce the risk of dying by 31% compared to ipilimumab.

    KEYTRUDA helped shrink tumors

    33% (91 of 277 patients) on KEYTRUDA given every 3 weeks saw their tumors shrink; 27% (74 of 277 patients) saw partial responses and 6% (17 of 277 patients) saw complete responses. This is compared to 12% (33 of 278 patients) on ipilimumab who saw their tumors shrink; 10% (29 of 278 patients) saw partial responses and 1% (4 of 278 patients) saw complete responses.

  • KEYTRUDA Reduced the Risk of Disease Progression by 42% Compared to Another Immunotherapy

    KEYTRUDA reduced the risk of disease progression by 42%

    KEYTRUDA given every 3 weeks reduced the risk of cancer spreading, growing, or getting worse by 42% compared to ipilimumab.

    Half of the patients on KEYTRUDA given every 3 weeks were alive without their cancer spreading, growing, or getting worse at 4.1 months, compared to 2.8 months for patients on ipilimumab.

How KEYTRUDA compared to chemotherapy

Another clinical trial compared patients with advanced melanoma who received the recommended dose of KEYTRUDA with those who received chemotherapy.

  • Results From a Clinical Trial Comparing KEYTRUDA to Chemotherapy

    Nearly 5 times as many patients on KEYTRUDA saw their tumors shrink

    21% (38 of 180 patients) on KEYTRUDA saw their tumors shrink; 19% (34 of 180 patients) saw partial responses and 2% (4 of 180 patients) saw complete responses. This is compared to 4% (8 of 179 patients) on chemotherapy who saw their tumors shrink; all of these patients saw partial responses and no complete responses were seen.

  • KEYTRUDA Reduced the Risk of Disease Progression by 43% Compared to Chemotherapy

    KEYTRUDA reduced the risk of disease progression by 43%

    KEYTRUDA reduced the risk of cancer spreading, growing, or getting worse by 43% compared to chemotherapy.

    Half of the patients on KEYTRUDA were alive without their cancer spreading, growing, or getting worse at 2.9 months, compared to 2.7 months for patients on chemotherapy.